EUVIMED · CrossrefZeitschrift
European Journal of Cancer Supplements
ISSN 1359-6349 · Elsevier BV
Neueste Artikel
Cardiovascular disease after cancer therapy
Sexual dysfunction and infertility as late effects of cancer treatment
Anxiety and sleep disorders in cancer patients
Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors
Radiotherapy for rectal cancer: Short course versus long course – When and how
Health-Related Quality of Life in EORTC clinical trials — 30 years of progress from methodological developments to making a real impact on oncology practice
2LBA Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study
41LBA Single institute phase II study of weekly cisplatinum and metronomic dosing of endoxan and methotrexate in second line metastatic breast cancer triple-negative
Retrospective analysis of chemotherapy choices and overall survival according to treatment in 96 patients >75 years old with metastatic breast cancer
Electrochemotherapy – An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study
646 POSTER Insights into the mechanism of microtubule stabilization by Taxol
The acute effects of adjuvant chemotherapy for breast cancer on cognitive function
Management of non-small cell lung cancer in elderly patients
New targets and new treatments in non-small cell lung cancer
New perspectives in the management of non-small cell lung cancer (NSCLC)
The role of imaging in screening, diagnosis and staging of Non-Small Cell Lung Cancer (NSCLC)
Management of small cell lung cancer
Status and trends of chemotherapy for advanced NSCLC
Bisphosphonates for metastatic bone disease
Reducing skeletal complications and bone pain with intravenous ibandronate for metastatic bone disease
Pharmacokinetic and clinical equivalence of oral and intravenous ibandronate for metastatic bone disease
Ibandronate
Oral daily ibandronate
Proteasome inhibition as a major advance in oncology
The clinical potential of proteasome inhibition
Proteasome inhibition: potential benefits in the treatment of cancer
Bortezomib in multiple myeloma: treatment approach and outcomes
Bortezomib: clinical profile in lymphoproliferative malignancies
Clinical potential of proteasome inhibition in solid tumours
Colorectal cancer in 2003: state of the art and new developments
EUVIMED